Your session is about to expire
← Back to Search
Flavonoid
Quercetin for Coronary Artery Disease (Q-CABG Trial)
Phase 2
Waitlist Available
Led By Michel Carrier, MD
Research Sponsored by Montreal Heart Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
To have had a myocardial infarction (MI) within the past 30 days or to be in a state of stable angina before the surgery
Be hospitalized and waiting for a cardiac surgery of revascularization
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 to 12 weeks post-surgery
Awards & highlights
Q-CABG Trial Summary
This trial will test whether quercetin can help reduce inflammation and the effects of aging during heart bypass surgery.
Who is the study for?
This trial is for adults who've had a heart attack in the last 30 days or have stable angina, awaiting coronary artery bypass surgery. They must speak French or English and consent to participate. Excluded are those without recent heart attacks, with infections, severe kidney/liver disease, estrogen-dependent tumor history, flavonoid intolerance, or taking certain medications.Check my eligibility
What is being tested?
The study examines Quercetin's potential to reduce inflammation and slow cell aging during coronary bypass surgery compared to a placebo. Participants will be randomly assigned to receive either Quercetin or an inactive substance.See study design
What are the potential side effects?
Quercetin may cause side effects such as headaches and tingling of the extremities; digestive discomfort like acid reflux and diarrhea; and could potentially interact with various medications.
Q-CABG Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I had a heart attack in the last 30 days or my chest pain is stable.
Select...
I am hospitalized and waiting for heart bypass surgery.
Q-CABG Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 1 day and 4 days post-surgery
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 1 day and 4 days post-surgery
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Quercetin-associated change in surgery-associated inflammation
Quercetin-associated change in surgery-associated marker of senescence
Secondary outcome measures
Quercetin-dependent change in endothelium-dependent relaxation
Quercetin-dependent change in senescent arterial wall cell load
Quercetin-dependent change in senescent endothelial cell load
Other outcome measures
Health status at follow-up visit.
Q-CABG Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: QuercetinActive Control1 Intervention
Patients receiving 500 mg quercetin twice daily
Group II: PlaceboPlacebo Group1 Intervention
Patients receiving placebo twice daily
Find a Location
Who is running the clinical trial?
Montreal Heart InstituteLead Sponsor
120 Previous Clinical Trials
68,719 Total Patients Enrolled
21 Trials studying Coronary Artery Disease
13,883 Patients Enrolled for Coronary Artery Disease
Michel Carrier, MDPrincipal InvestigatorMontreal Heart Institute
1 Previous Clinical Trials
3,000 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have had breast cancer or another estrogen-dependent tumor before.You are unable to tolerate flavonoids, niacin, or ascorbic acid.I am currently taking a quinolone medication.I had a heart attack in the last 30 days or my chest pain is stable.I need to take a quinolone antibiotic after surgery.My liver tests are more than twice the normal values.I cannot speak French or English.I am capable of understanding and consenting to participate.I am hospitalized and waiting for heart bypass surgery.I take quercetin supplements.I have had an infection in the past month.I have not had a heart attack in the last 30 days.I am having another heart surgery along with my bypass surgery.I have been diagnosed with cirrhosis.I can speak French or English.My kidney function is low (GFR below 30).
Research Study Groups:
This trial has the following groups:- Group 1: Quercetin
- Group 2: Placebo
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many participants are enrolled in the current clinical trial?
"Affirmative, the information on clinicaltrials.gov states that this trial is presently enrolling patients. The research study was initially listed on June 4th 2021 and has been recently modified as of April 4th 2022. A total of 100 individuals are needed from 1 medical centre for the experiment to proceed."
Answered by AI
Are there any extant studies devoted to the efficacy of Quercetin?
"At the moment, 10 clinical trials for Quercetin are underway. None of these research initiatives have reached Phase 3 yet, but they span multiple locations including Montréal in Quebec."
Answered by AI
Are there any remaining openings for this research study?
"As per information on clinicaltrials.gov, this medical trial is accepting patients at the moment and has been actively so since June 4th 2021. It was most recently updated on April 4th 2022."
Answered by AI
What hazards might accompany the consumption of Quercetin?
"Quercetin's safety rating on a 1-3 scale is 2, due to the fact that this study is only in Phase 2 and there are not yet any reports of its efficacy."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger